Neuroprotection in Alzheimer's Disease
Coordonnateur : Gozes Illana
Neuroprotection in Alzheimer?s Disease offers a translational point-of-view from both basic and clinical standpoints, putting it on the cusp for further clinical development with its emphasis on nerve cell protection, including the accumulation of knowledge from failed clinical trials and new advances in disease management.
This book brings together the latest findings, both basic, and clinical, under the same cover, making it easy for the reader to obtain a complete overview of the state-of-the-field and beyond. Alzheimer's disease is the most common form of dementia, accounting for 60 to 80 percent of dementia cases. It is a progressive brain disease that slowly destroys memory, thinking skills, and eventually, even the ability to carry out the simplest tasks. It is characterized by death of synapses coupled to death nerve cells and brain degeneration which is manifested by loss of cognitive abilities. Understanding neuroprotection in Alzheimer?s disease will pave the path to better disease management and novel therapeutics.
2. Neural regeneration as a disease modifying therapeutic strategy for Alzheimer's disease
3. Animal models
4. Mechanisms of Neuronal Microtubule Loss in Alzheimer’s Disease
5. Tau-centric therapies for treating Alzheimer’s Disease
6. The potential of small molecules in preventing tau oligomers formation and toxicity
7. A novel neuroprotection target with distinct regulation in stroke and Alzheimer´s disease
8. Sirtuin modulation as novel neuroprotective strategy for Alzheimer's Disease
9. Rescue of neurons by resolving inflammation
10. Targeting transition metals for neuroprotection in Alzheimer’s disease
11. Multifunctional effect of human serum albumin towards neuroprotection in Alzheimer disease
12. RGS2 and SIRT1 link renin angiotensin aldosterone system to Alzheimer’s disease
13. Neuroprotective drug development: the story of ADNP, NAP (davunetide) and SKIP
- Comprehensive reference detailing neuroprotection in Alzheimer’s Disease, with details on nerve cell protection and new advances in disease management
- Combines the knowledge and points-of-view of both medical doctors and basic scientists, putting the subject at the forefront for further clinical development
- Edited by one of the leading researchers in Alzheimer’s Disease
Date de parution : 01-2017
Ouvrage de 342 p.
15.2x22.8 cm
Thème de Neuroprotection in Alzheimer's Disease :
Mots-clés :
Aβ; activity-dependent neuroprotective protein (ADNP); albumin; Alzheimer; Alzheimer disease; Alzheimer's; Alzheimer's disease; Alzheimer's disease (AD); amyloid; amyloid β; amyloid processing; ApoE; APP; beta amyloid; blood-brain barrier; brain-derived neurotrophic factor (BDNF); calpain; cell-penetrating peptide; ciliary neurotrophic factor (CNTF); cognition; cognitive impairment; copper; creatine; cytoskeleton; davunetide; DLGAP1; drug development; Epothilone D; excitotoxicity; fidgetin; gene; genomic biomarkers; GSK-3β; GSK3; histone deacetylase; homeostasis; inflammation; iron; Kidins220; magnetic resonance spectroscopy; microglia; microtubule; microtubule degradation; microtubule destabilization; microtubule severing; microtubules; mild cognitive impairment (MCI); myelin; NAP (davunetide); neural regeneration; neurodegeneration; neurogenesis; neuroinflammation; neuron; neuronal and synaptic plasticity; neuroprotection; oligomers; pathological tau; phosphorylation; renin-angiotensin-aldosterone system; resolution; resveratrol; RGS2; SIRT1; sirtuin; sirtuin modulators; SKIP; small molecules; specialized proresolving lipid mediators; stroke; tau; tau aggregation; tau hyperphosphorylation; tau oligomers; tau pathology; tauopathy; therapeutics; therapy; transgenic models; zinc